An observational study in Liver Cirrhosis, Cancer and Cachexia, sponsored by Universitatsmedizin Mainz - 1. Medizinische Klinik. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-17.
Sponsored by Universitatsmedizin Mainz - 1. Medizinische Klinik · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Liver Cirrhosis with a site in Germany — 24 open to participants now, 27 under way, 2 of them phase 3. Liver Cirrhosis · Germany.
Among the 82 studies in Liver Cirrhosis with a site in Germany, this one is the 19th largest by planned enrollment of the 37 observational ones that give a count, is one of 6 that started in 2024, is one of 37 observational ones, reaches primary completion later than 11 of the 26 other live ones, and was the 75th registered.
1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →24 of the 82 studies in Liver Cirrhosis with a site in Germany are open now. Recruiting first, the newest first:
University Hospital Muenster · Sites in Germany
Ages 18+
University Medical Center Groningen · Sites in Germany, Austria, Belgium and 9 more countries
Ages 18+
Hannover Medical School · Sites in Germany
Ages 18–99 · Healthy volunteers
University Hospital Freiburg · Sites in Germany
Ages 18–80
Boehringer Ingelheim · Sites in Germany, United States, Argentina and 34 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 20 · Phase 3 8 · Phase 4 3
First in 2000; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 172 across 528 observational studies indexed under Liver Cirrhosis.
Median enrollment 110 across the 43 interventional studies, 200 across the 37 observational. Of the 51 that completed or were terminated, 18 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 82 have an industry lead sponsor. The 10 most frequent:
Universitatsmedizin Mainz - 1. Medizinische Klinik is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Universitatsmedizin Mainz - 1. Medizinische Klinik has 1 study filed under Liver Cirrhosis — fewer than ten, so there is no comparison to draw.
3 of the studies in Liver Cirrhosis with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05500222Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | 2026-12 |
| NCT07585890University Medical Center GroningenEstablishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe | 2026-12-31 |
| NCT04613921European Foundation for Study of Chronic Liver FailureLiver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 82 studies in Liver Cirrhosis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Frailty is a geriatric syndrome that primarily affects older patients, but also patients with severe illnesses. It is particularly common among oncology patients, but also among patients with gastrointestinal diseases such as liver cirrhosis or pancreatitis. Sarcopenia, a form of frailty, is defined as a loss of muscle quantity, quality and function. Currently, complex methods such as CT or bioimpedance measurement are available. However, simpler techniques such as ultrasound-based measurement could be alternatives, but still require further validation. In addition, serological muscle markers could support and simplify diagnostics.
The aim of this project is to be able to estimate the prognosis of patients at an early stage by measuring sarcopenia using ultrasound and biomarkers.
Frailty is a well-known syndrome that has a negative impact on many diseases and the course of disease. Patients affected by frailty are particularly vulnerable due to their inadequate ability to deal with extrinsic and intrinsic stressors. The prevalence of frailty increases with age, affecting 15% of people over the age of 65 and 25% of people over the age of 80.
Frailty is the end result of an interplay between malnutrition, cognitive impairment and muscle wasting. Each of these factors can be further examined and measured, but they also influence each other. In particular, reduced muscle mass and muscle function have been associated with poor quality of life and a worse course of disease. Sarcopenia is therefore becoming an increasingly important factor in various disease patterns and should be monitored further. Muscle atrophy and sarcopenia have multifactorial causes. Physical inactivity, chronic inflammation associated with chronic diseases, and malnutrition are particularly important in this context. Cross-sectional measurement of several muscles at the level of the lumbar vertebrae (L3), normalized to body size, and dual X-ray absorptiometry are currently the most commonly used techniques for measuring sarcopenia. However, complex equipment and procedures are required for the measurements. Furthermore, radiological imaging is costly and causes radiation exposure. Therefore, attempts have been made in the past to simplify the measurements. Sonographic measurement is a practical alternative. Many different muscle groups are accessible to ultrasound. In particular, the thigh muscles and the psoas major muscle can be easily visualized using sonography. The sonographic assessment of the psoas muscle area index (PMAI) and the thigh muscle thickness index (TMTI) are approaches to bedside morphometry that we use primarily.
Currently, little is known about serological muscle parameters. Measurement in the blood would be more elegant than sonographic muscle measurement. This would save additional instrumental diagnostics and still provide an impression of the musculature and thus possibly of the patient's fitness. Various biomarkers come into question for this. In particular, markers of muscle protein synthesis such as activin A/B and myostatin have already been described in individual collectives. However, biomarkers require further research, especially in various disease entities.
The investigators expect sonographic and laboratory measurements of the musculature to provide a better assessment of prognosis, quality of life and functional results during therapy.
oncological patient in the field of gastrointestinal tumors patients with liver cirrhosis patients attending the intensive care unit
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Sonographisch measurement of muscles Blood muscle markers
Complication
Number of patients with decompensation of the underlying disease (e.g. liver cirrhosis: hyropic decompensation) or hospitalisation or death
Time frame: From the date of enrollment until the date of first documented complication (decopmensation, hospitalisation, death) from any cause whichever came first, assessed up to two years
Plan to share: Undecided — We will make the data available accordingly in the context of publications.
Started Oct 2024 (actual). Primary completion is estimated for Oct 2026, 24 months after the start.
Of 231 non-industry observational studies under Liver Cirrhosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 24 months is below that.
Counting every sponsor, half of 247 studies reached it within 47 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitatsmedizin Mainz - 1. Medizinische Klinik